Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Markets

Pharmacy Facelift: How Walgreens and CVS Aim to Boost Profits

by Team Lumida
May 17, 2024
in Markets, News
Reading Time: 4 mins read
A A
0
woman with face mask holding an alcohol bottle

Photo by Anna Tarazevich on Pexels.com

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

  1. Walgreens and CVS are redesigning stores to emphasize health and wellness.
  2. Rising competition and falling margins drive these changes.
  3. Investors should watch for potential improvements in profitability and customer satisfaction.

What Happened?

Walgreens and CVS are drastically revamping their store layouts to focus on health and wellness, aiming to counter sagging performance. Walgreens, for example, is testing a new store design in Aubrey, Texas, where the pharmacy counter is moved to the front, and customers use self-service kiosks.

CVS is integrating its Oak Street Health primary-care centers into some stores. Both chains have seen significant declines in operating margins, with Walgreens’ U.S. pharmacy operating margin dropping to -5% last year. These redesign efforts are part of broader strategies to improve efficiency and customer experience amid fierce competition from Amazon, Dollar General, and Walmart.

Why It Matters?

These changes are crucial as both Walgreens and CVS struggle with falling margins and investor dissatisfaction. Walgreens’ shares have plummeted 77% over the past decade, and CVS’ shares have dropped 26%.

By making pharmacies more customer-friendly and efficient, they aim to attract more customers and boost profitability. These efforts are essential for long-term sustainability, especially given the increasing role of pharmacists in healthcare services, such as vaccinations and testing.

What’s Next?

Investors should monitor the success of these pilot stores and any subsequent rollouts. If these new designs prove effective, we could see a broader implementation, potentially improving the financial outlook for both companies.

Additionally, keep an eye on the labor situation; reducing pharmacists’ workloads could enhance service quality and customer satisfaction. The success of these initiatives could also pressure competitors to innovate, potentially reshaping the entire pharmacy landscape.

Source: Bloomberg
Previous Post

Medicare Shakeup: Policy Changes Rattle Big Insurers

Next Post

Revolutionizing AI: How DePIN is Solving Robots’ Biggest Blind Spot

Recommended For You

KKR Lifts Its 10-Year Treasury Call to 5.1% and Pushes the Fed Hold Out to Early 2029

by Team Lumida
13 hours ago
KKR Lifts Its 10-Year Treasury Call to 5.1% and Pushes the Fed Hold Out to Early 2029

KKR now expects hikes in December and March, then rates held at that level for nearly three years, citing Warsh concern over persistent inflation.

Read more

JPMorgan Puts Oil Fair Value at $90 Against a $106 Price, Implying 4 Million Barrels a Day of Additional Loss Risk

by Team Lumida
13 hours ago
Dollar Steadies, Euro and Sterling Vulnerable as Markets Await Fed Decision; Bitcoin Trades at 4-Week Lows

Six months into the Iran war, JPMorgan says every economic red line it assumed Washington would not cross has been crossed, leaving no model for how it ends.

Read more

Three New ETFs Target Tax Deferral, Next-Generation AI Winners and Hedged Bitcoin Exposure

by Team Lumida
14 hours ago
Three New ETFs Target Tax Deferral, Next-Generation AI Winners and Hedged Bitcoin Exposure

Bloomberg Trillions reviews three recent ETF launches covering tax-deferred structures, an AI index beyond the megacaps, and a hedged bitcoin product.

Read more

Chip Gauge Jumps 3% and 10-Year Yields Snap an Eight-Day Rising Streak as Brent Slides to $104

by Team Lumida
14 hours ago
S&P 500’s Big Earnings Test: Will Tech Slowdown Derail Gains?

Stocks and bonds rallied the day after the Fed first hike since 2023, driven by falling oil rather than anything the central bank said.

Read more

Shorts Take $208 Million of a $345 Million Liquidation Wave as Bitcoin Holds $76,000 Through the Fed Hike

by Team Lumida
20 hours ago
SEC Approval Boosts Crypto Funds: $1.2B Invested in a Week

Bitcoin barely moved on the Fed first hike of the cycle while 86,816 traders were liquidated, with bears absorbing most of the damage and Zcash running 17%.

Read more

US Stock Futures Rally Post-Fed as Oil Falls, Treasury Yields Decline; Nasdaq 100 Futures Up 1.1%, Tech Leads Rebound

by Team Lumida
20 hours ago
US Stock Futures Rally Post-Fed as Oil Falls, Treasury Yields Decline; Nasdaq 100 Futures Up 1.1%, Tech Leads Rebound

S&P 500 futures +0.8%, Nasdaq 100 futures +1.1% as Brent crude falls 2.2%; semiconductors surge on lower yields supporting AI demand.

Read more

Novo Nordisk Partners With Orbis for Oral Biologic Pills Worth $1.4B; Eli Lilly Also Stakeholder in AI Drug Design Startup

by Team Lumida
20 hours ago
Novo Nordisk Partners With Orbis for Oral Biologic Pills Worth $1.4B; Eli Lilly Also Stakeholder in AI Drug Design Startup

Novo invests in Orbis to develop oral versions of Ozempic/Wegovy; Orbis uses AI for compound design; Eli Lilly competing as stakeholder.

Read more

How to Bet on Oil Without Owning a Barrel: Retail Traders Navigate Crude Products From ETFs to Perpetual Futures

by Team Lumida
21 hours ago
How to Bet on Oil Without Owning a Barrel: Retail Traders Navigate Crude Products From ETFs to Perpetual Futures

Energy ETFs (XLE, VDE) safest; futures-linked (USO, BNO) track crude but face contango drag; dynamic roll funds (DBO, USL) mitigate; crypto/blockchain/perps carry high risk.

Read more

Treasuries Surge on Warsh Credibility; 10-Year Yields Fall to 4.98% After Fed Rate Hike Signals Inflation Fight Commitment

by Team Lumida
21 hours ago
BlackRock’s Larry Fink on Economic Growth and Market Misconceptions

Bond market rallies on confidence in Fed Chair; 10-year yields fall 4bps from 5% peak; BOJ, BOE meetings Thursday could extend global rate-hike cycle.

Read more

China’s US Treasury Holdings Hit 18-Year Low at $618B; Geopolitical Rift and Yield Spike Fears Drive Diversification to Gold, Agency Bonds

by Team Lumida
23 hours ago
China’s US Treasury Holdings Hit 18-Year Low at $618B; Geopolitical Rift and Yield Spike Fears Drive Diversification to Gold, Agency Bonds

China reduces Treasury holdings to lowest since Aug 2008 from $1.3T peak; diversifies into gold, agency bonds, equities as US debt surpasses $40T.

Read more
Next Post

Revolutionizing AI: How DePIN is Solving Robots’ Biggest Blind Spot

NFT Nightmare: Dolce & Gabbana Sued Over NFT Misstep

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Berkshire Hathaway Plans Yen Bond Amid Global Debt Binge

Berkshire Hathaway Plans Yen Bond Amid Global Debt Binge

November 6, 2025
China’s Bold Economic Moves: What You Need to Know Now

China’s Economy Unexpectedly Weakens Across the Board in April

May 18, 2026
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

Trump Creates $1.78 Billion Fund to Compensate People Who Claim the Government Targeted Them

May 19, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018